|
1
|
Xie J, Xiao X, Dong Z and Wang Q: The
systemic inflammation score is associated with the survival of
patients with prostate cancer. J Inflamm Res. 16:963–975. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tan Y, Wang L, Du Y, Liu X, Chen Z, Weng
X, Guo J, Chen H, Wang M and Wang X: Inhibition of BRD4 suppresses
tumor growth in prostate cancer via the enhancement of FOXO1
expression. Int J Oncol. 53:2503–2517. 2018.PubMed/NCBI
|
|
4
|
Dong D, Zhang L, Bai C, Ma N, Ji W, Jia L,
Zhang A, Zhang P, Ren L and Zhou Y: UNC5D, suppressed by promoter
hypermethylation, inhibits cell metastasis by activating
death-associated protein kinase 1 in prostate cancer. Cancer Sci.
110:1244–1255. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Belmonte M, Saia G, Zugni F, Alessi S,
Colombo A, Summers PE, Luzzago S, Marvaso G, Musi G, De Cobelli O,
et al: The role of MRI in the management of a prostate cancer
patient with bone and lymph nodes metastases. A case report. Acta
Biomed. 92:e20212142021.PubMed/NCBI
|
|
6
|
Witt K, Evans-Axelsson S, Lundqvist A,
Johansson M, Bjartell A and Hellsten R: Inhibition of STAT3
augments antitumor efficacy of anti-CTLA-4 treatment against
prostate cancer. Cancer Immunol Immunother. 70:3155–3166. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sun CY, Talukder M, Cao D and Chen CW:
Gilteritinib enhances Anti-tumor efficacy of CDK4/6 inhibitor,
abemaciclib in lung cancer cells. Front Pharmacol. 13:8297592022.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rysanek D, Vasicova P, Kolla JN, Sedlak D,
Andera L, Bartek J and Hodny Z: Synergism of BCL-2 family
inhibitors facilitates selective elimination of senescent cells.
Aging. 14:6381–6414. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rhinn M, Zapata-Bodalo I, Klein A, Plassat
JL, Knauer-Meyer T and Keyes WM: Aberrant induction of
p19Arf-mediated cellular senescence contributes to
neurodevelopmental defects. PLoS Biol. 20:e30016642022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Alessio N, Aprile D, Squillaro T, Di
Bernardo G, Finicelli M, Melone MA, Peluso G and Galderisi U: The
senescence-associated secretory phenotype (SASP) from mesenchymal
stromal cells impairs growth of immortalized prostate cells but has
no effect on metastatic prostatic cancer cells. Aging (Albany NY).
11:5817–5828. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kallenbach J, Atri Roozbahani G, Heidari
Horestani M and Baniahmad A: Distinct mechanisms mediating
therapy-induced cellular senescence in prostate cancer. Cell
Biosci. 12:2002022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mori JO, Elhussin I, Brennen WN, Graham
MK, Lotan TL, Yates CC, De Marzo AM, Denmeade SR, Yegnasubramanian
S, Nelson WG, et al: Prognostic and therapeutic potential of
senescent stromal fibroblasts in prostate cancer. Nat Rev Urol.
21:258–273. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takemoto K, Kobatake K, Miura K, Fukushima
T, Babasaki T, Miyamoto S, Sekino Y, Kitano H, Goto K, Ikeda K, et
al: BACH1 promotes clear cell renal cell carcinoma progression by
upregulating oxidative stress-related tumorigenicity. Cancer Sci.
114:436–448. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hayflick L and Moorhead PS: The serial
cultivation of human diploid cell strains. Exp Cell Res.
25:585–621. 1961. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang Y, Ge MX, Li YH, Li JL, Yu Q, Xiao
FH, Ao HS, Yang LQ, Li J, He Y and Kong QP: Longevity-associated
transcription factor ATF7 promotes Healthspan by suppressing
cellular senescence and systematic inflammation. Aging Dis.
14:1374–1389. 2023.PubMed/NCBI
|
|
16
|
Ngoi NY, Liew AQx, Chong SJF, Davids MS,
Clement MV and Pervaiz S: The redox-senescence axis and its
therapeutic targeting. Redox Biol. 45:1020322021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park SS, Choi YW, Kim JH, Kim HS and Park
TJ: Senescent tumor cells: An overlooked adversary in the battle
against cancer. Exp Mol Med. 53:1834–1841. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alhaddad L, Nofal Z, Pustovalova M, Osipov
AN and Leonov S: Long-term cultured human glioblastoma multiforme
cells demonstrate increased radiosensitivity and
senescence-associated secretory phenotype in response to
irradiation. Int J Mol Sci. 24:20022023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu Z, Uhl B, Gires O and Reichel CA: A
transcriptomic pan-cancer signature for survival prognostication
and prediction of immunotherapy response based on endothelial
senescence. J Biomed Sci. 30:212023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mirzakhani K, Kallenbach J, Rasa SMM,
Ribaudo F, Ungelenk M, Ehsani M, Gong W, Gassler N, Leeder M, Grimm
MO, et al: The androgen receptor-lncRNASAT1-AKT-p15 axis mediates
androgen-induced cellular senescence in prostate cancer cells.
Oncogene. 41:943–959. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Birch J and Gil J: Senescence and the
SASP: Many therapeutic avenues. Genes Dev. 34:1565–1576. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Coppé JP, Patil CK, Rodier F, Sun Y, Muñoz
DP, Goldstein J, Nelson PS, Desprez PY and Campisi J:
Senescence-associated secretory phenotypes reveal
cell-nonautonomous functions of oncogenic RAS and the p53 tumor
suppressor. PLoS Biol. 6:2853–2868. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Georgilis A, Klotz S, Hanley CJ, Herranz
N, Weirich B, Morancho B, Leote AC, D'Artista L, Gallage S,
Seehawer M, et al: PTBP1-mediated alternative splicing regulates
the inflammatory Secretome and the Pro-tumorigenic effects of
senescent cells. Cancer Cell. 34:85–102.e9. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yue Z, Nie L, Zhao P, Ji N, Liao G and
Wang Q: Senescence-associated secretory phenotype and its impact on
oral immune homeostasis. Front Immunol. 13:10193132022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu L, Yue X, Sun Z, Hambright WS, Wei J,
Li Y, Matre P, Cui Y, Wang Z, Rodney G, et al: Reduction of
senescent fibro-adipogenic progenitors in progeria-aged muscle by
senolytics rescues the function of muscle stem cells. J Cachexia
Sarcopenia Muscle. 13:3137–3148. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Khalil R, Diab-Assaf M and Lemaitre JM:
Emerging therapeutic approaches to target the dark side of
senescent cells: New hopes to treat aging as a disease and to delay
age-related pathologies. Cells. 12:9152023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang L, Pitcher LE, Yousefzadeh MJ,
Niedernhofer LJ, Robbins PD and Zhu Y: Cellular senescence: A key
therapeutic target in aging and diseases. J Clin Invest.
132:e1584502022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Duan D, Shang M, Han Y, Liu J, Liu J, Kong
SH, Hou J, Huang B, Lu J and Zhang Y: EZH2-CCF-cGAS axis promotes
breast cancer metastasis. Int J Mol Sci. 23:17882022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang M, Cha Z, Liu R, Lin M, Gafoor NA,
Kong T, Ge F and Chen W: Enhancing immunotherapy outcomes by
targeted remodeling of the tumor microenvironment via combined
cGAS-STING pathway strategies. Front Immunol. 15:13999262024.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee KS, Lin S, Copland DA, Dick AD and Liu
J: Cellular senescence in the aging retina and developments of
senotherapies for age-related macular degeneration. J
Neuroinflammation. 18:322021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Toso A, Revandkar A, Di Mitri D, Guccini
I, Proietti M, Sarti M, Pinton S, Zhang J, Kalathur M, Civenni G,
et al: Enhancing chemotherapy efficacy in Pten-Deficient prostate
tumors by activating the senescence-associated antitumor immunity.
Cell Rep. 9:75–89. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Parry AJ, Hoare M, Bihary D,
Hänsel-Hertsch R, Smith S, Tomimatsu K, Mannion E, Smith A,
D'Santos P, Russell IA, et al: NOTCH-mediated non-cell autonomous
regulation of chromatin structure during senescence. Nat Commun.
9:18402018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tan SYX, Zhang J and Tee WW: Epigenetic
regulation of inflammatory signaling and inflammation-induced
cancer. Front Cell Dev Biol. 10:9314932022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chandrasekaran A, Idelchik MDPS and
Melendez JA: Redox control of senescence and age-related disease.
Redox Biol. 11:91–102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Takasugi M, Yoshida Y and Ohtani N:
Cellular senescence and the tumour microenvironment. Mol Oncol.
16:3333–3351. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wan R, Long S, Ma S, Yan P, Li Z, Xu K,
Lian H, Li W, Duan Y, Zhu M, et al: NR2F2 alleviates pulmonary
fibrosis by inhibition of epithelial cell senescence. Respir Res.
25:1542024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhao B, Wu B, Feng N, Zhang X, Zhang X,
Wei Y and Zhang W: Aging microenvironment and antitumor immunity
for geriatric oncology: the landscape and future implications. J
Hematol OncolJ Hematol Oncol. 16:282023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hwang HJ, Lee YR, Kang D, Lee HC, Seo HR,
Ryu JK, Kim YN, Ko YG, Park HJ and Lee JS: Endothelial cells under
therapy-induced senescence secrete CXCL11, which increases
aggressiveness of breast cancer cells. Cancer Lett. 490:100–110.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chibaya L, Snyder J and Ruscetti M:
Senescence and the tumor-immune landscape: Implications for cancer
immunotherapy. Semin Cancer Biol. 86:827–845. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Volonte D and Galbiati F: Caveolin-1, a
master regulator of cellular senescence. Cancer Metastasis Rev.
39:397–414. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pardella E, Pranzini E, Nesi I, Parri M,
Spatafora P, Torre E, Muccilli A, Castiglione F, Fambrini M, Sorbi
F, et al: Therapy-induced stromal senescence promoting
aggressiveness of prostate and ovarian cancer. Cells. 11:40262022.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xu MY, Xia ZY, Sun JX, Liu CQ, An Y, Xu
JZ, Zhang SH, Zhong XY, Zeng N, Ma SY, et al: A new perspective on
prostate cancer treatment: The interplay between cellular
senescence and treatment resistance. Front Immunol. 15:13950472024.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Meng F, Han X, Min Z, He X and Zhu S:
Prognostic signatures associated with high infiltration of Tregs in
bone metastatic prostate cancer. Aging. 13:17442–17461. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gilbert S, Péant B, Malaquin N, Tu V,
Fleury H, Leclerc-Desaulniers K, Rodier F, Mes-Masson AM and Saad
F: Targeting IKKε in androgen-independent prostate cancer causes
phenotypic senescence and genomic instability. Mol Cancer Ther.
21:407–418. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pernicová Z, Slabáková E, Kharaishvili G,
Bouchal J, Král M, Kunická Z, Machala M, Kozubík A and Souček K:
Androgen depletion induces senescence in prostate cancer cells
through down-regulation of Skp2. Neoplasia. 13:526–536. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Blute ML, Damaschke N, Wagner J, Yang B,
Gleave M, Fazli L, Shi F, Abel EJ, Downs TM, Huang W and Jarrard
DF: Persistence of senescent prostate cancer cells following
prolonged neoadjuvant androgen deprivation therapy. PLoS One.
12:e01720482017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang X, Peng Y, Yuan Y, Gao Y, Hu F, Wang
J, Zhu X, Feng X, Cheng Y, Wei Y, et al: Histone methyltransferase
SET8 is regulated by miR-192/215 and induces oncogene-induced
senescence via p53-dependent DNA damage in human gastric carcinoma
cells. Cell Death Dis. 11:9372020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tao YP, Zhu HY, Shi QY, Wang CX, Hua YX,
Hu HY, Zhou QY, Zhou ZL, Sun Y, Wang XM, et al: S1PR1 regulates
ovarian cancer cell senescence through the PDK1-LATS1/2-YAP
pathway. Oncogene. 42:3491–3502. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fang L, Li D, Yin J, Pan H, Ye H, Bowman
J, Capaldo B and Kelly K: TMPRSS2-ERG promotes the initiation of
prostate cancer by suppressing oncogene-induced senescence. Cancer
Gene Ther. 29:1463–1476. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Saleh T, Khasawneh AI, Himsawi N,
Abu-Raideh J, Ejeilat V, Elshazly AM and Gewirtz DA: Senolytic
therapy: A potential approach for the elimination of
oncogene-induced senescent HPV-positive cells. Int J Mol Sci.
23:155122022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ye M, Huang X, Wu Q and Liu F: Senescent
stromal cells in the tumor microenvironment: Victims or
accomplices? Cancers. 15:19272023. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Brandmaier A, Hou SQ and Shen WH: Cell
cycle control by PTEN. J Mol Biol. 429:2265–2277. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhou X, Yang X, Sun X, Xu X, Li X, Guo Y,
Wang J, Li X, Yao L, Wang H and Shen L: Effect of PTEN loss on
metabolic reprogramming in prostate cancer cells. Oncol Lett.
17:2856–2866. 2019.PubMed/NCBI
|
|
54
|
Parisotto M, Grelet E, El Bizri R, Dai Y,
Terzic J, Eckert D, Gargowitsch L, Bornert JM and Metzger D: PTEN
deletion in luminal cells of mature prostate induces replication
stress and senescence in vivo. J Exp Med. 215:1749–1763. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chen Z, Carracedo A, Lin HK, Koutcher JA,
Behrendt N, Egia A, Alimonti A, Carver BS, Gerald W,
Teruya-Feldstein J, et al: Differential p53-independent outcomes of
p19(Arf) loss in oncogenesis. Sci Signal. 2:ra442009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Guo J, Huang X, Dou L, Yan M, Shen T, Tang
W and Li J: Aging and aging-related diseases: From molecular
mechanisms to interventions and treatments. Signal Transduct Target
Ther. 7:3912022. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hua H, Zheng C, Fan J, Li X, Xie W, Chen J
and Yu C: The senescence-related signature predicts prognosis and
characterization of tumor microenvironment infiltration in
pancreatic cancer. BioMed Res Int. 2022:1–28. 2022. View Article : Google Scholar
|
|
58
|
Dyachkova U, Vigovskiy M, Basalova N,
Efimenko A and Grigorieva O: M2-Macrophage-induced chronic
inflammation promotes reversible mesenchymal stromal cell
senescence and reduces their anti-fibrotic properties. Int J Mol
Sci. 24:170892023. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Stanojković TP, Matić IZ, Petrović N,
Stanković V, Kopčalić K, Besu I, Đorđić Crnogorac M, Mališić E,
Mirjačić-Martinović K, Vuletić A, et al: Evaluation of cytokine
expression and circulating immune cell subsets as potential
parameters of acute radiation toxicity in prostate cancer patients.
Sci Rep. 10:190022020. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
González-Ochoa S, Tellez-Bañuelos MC,
Méndez-Clemente AS, Bravo-Cuellar A, Hernández Flores G,
Palafox-Mariscal LA, Haramati J, Pedraza-Brindis EJ, Sánchez-Reyes
K and Ortiz-Lazareno PC: Combination blockade of the IL6R/STAT-3
Axis with TIGIT and its impact on the functional activity of NK
cells against prostate cancer cells. J Immunol Res.
2022:18108042022. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Méndez-Clemente A, Bravo-Cuellar A,
González-Ochoa S, Santiago-Mercado M, Palafox-Mariscal L,
Jave-Suárez L, Solorzano-Ibarra F, Villaseñor-García M,
Ortiz-Lazareno P and Hernández-Flores G: Dual STAT-3 and IL-6R
inhibition with stattic and tocilizumab decreases migration,
invasion and proliferation of prostate cancer cells by targeting
the IL-6/IL-6R/STAT-3 axis. Oncol Rep. 48:1382022. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Silk N, Reich J, Sinha R, Chawla S, Geary
K and Zhang D: The effects of resveratrol on prostate cancer
through targeting the tumor microenvironment. J Xenobiotics.
11:16–32. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Park SY, Cui Z, Kim B, Park G and Choi YW:
Treatment with gold nanoparticles using cudrania tricuspidata root
extract induced downregulation of MMP-2/-9 and PLD1 and inhibited
the invasiveness of human U87 Glioblastoma cells. Int J Mol Sci.
21:12822020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Fahs A, Hussein N, Zalzali H, Ramadan F,
Ghamloush F, Tamim H, El Homsi M, Badran B, Boulos F, Tawil A, et
al: CD147 promotes tumorigenesis via Exosome-mediated signaling in
rhabdomyosarcoma. Cells. 11:22672022. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Bair EL, Chen ML, McDaniel K, Sekiguchi K,
Cress AE, Nagle RB and Bowden GT: Membrane type 1 Matrix
Metalloprotease cleaves Laminin-10 and promotes prostate cancer
cell migration. Neoplasia. 7:380–389. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Wei R, Wong JPC, Lyu P, Xi X, Tong O,
Zhang SD, Yuen HF, Shirasawa S and Kwok HF: In vitro and clinical
data analysis of Osteopontin as a prognostic indicator in
colorectal cancer. J Cell Mol Med. 22:4097–4105. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Miftakhova R, Hedblom A, Semenas J,
Robinson B, Simoulis A, Malm J, Rizvanov A, Heery DM, Mongan NP,
Maitland NJ, et al: Cyclin A1 and P450 aromatase promote metastatic
homing and growth of Stem-like prostate cancer cells in the bone
marrow. Cancer Res. 76:2453–2464. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Guccini I, Revandkar A, D'Ambrosio M,
Colucci M, Pasquini E, Mosole S, Troiani M, Brina D,
Sheibani-Tezerji R, Elia AR, et al: Senescence reprogramming by
TIMP1 deficiency promotes prostate cancer metastasis. Cancer Cell.
39:68–82.e9. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Rodier F, Coppé JP, Patil CK, Hoeijmakers
WA, Muñoz DP, Raza SR, Freund A, Campeau E, Davalos AR and Campisi
J: Persistent DNA damage signalling triggers senescence-associated
inflammatory cytokine secretion. Nat Cell Biol. 11:973–979. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
van Dessel LF, van Riet J, Smits M, Zhu Y,
Hamberg P, van der Heijden MS, Bergman AM, van Oort IM, de Wit R,
Voest EE, et al: The genomic landscape of metastatic
castration-resistant prostate cancers reveals multiple distinct
genotypes with potential clinical impact. Nat Commun. 10:52512019.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Aggarwal M, Saxena R, Asif N, Sinclair E,
Tan J, Cruz I, Berry D, Kallakury B, Pham Q, Wang TTY and Chung FL:
p53 mutant-type in human prostate cancer cells determines the
sensitivity to phenethyl isothiocyanate induced growth inhibition.
J Exp Clin Cancer Res. 38:3072019. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Wanjala J, Taylor BS, Chapinski C,
Hieronymus H, Wongvipat J, Chen Y, Nanjangud GJ, Schultz N, Xie Y,
Liu S, et al: Identifying actionable targets through integrative
analyses of GEM model and human prostate cancer genomic profiling.
Mol Cancer Ther. 14:278–288. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Haffner MC, Mosbruger T, Esopi DM, Fedor
H, Heaphy CM, Walker DA, Adejola N, Gürel M, Hicks J, Meeker AK, et
al: Tracking the clonal origin of lethal prostate cancer. J Clin
Invest. 123:4918–4922. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Ding D, Blee AM, Zhang J, Pan Y, Becker
NA, Maher LJ III, Jimenez R, Wang L and Huang H: Gain-of-function
mutant p53 together with ERG proto-oncogene drive prostate cancer
by beta-catenin activation and pyrimidine synthesis. Nat Commun.
14:46712023. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Jiang SJ and Wang S: Dual targeting of
mTORC1 and mTORC2 by INK-128 potently inhibits human prostate
cancer cell growth in vitro and in vivo. Tumour Biol. 36:8177–8184.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Shorning BY, Dass MS, Smalley MJ and
Pearson HB: The PI3K-AKT-mTOR pathway and prostate cancer: At the
crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci.
21:45072020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Shi J, Liu C, Chen C, Guo K, Tang Z, Luo
Y, Chen L, Su Y and Xu K: Circular RNA circMBOAT2 promotes prostate
cancer progression via a miR-1271-5p/mTOR axis. Aging (Albany NY).
12:13255–13280. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Li Y, Fan A, Zhang Y, Guo Z, Meng W, Pan
W, Ma Z and Chen W: Cellular senescence: A potential mode of
circular RNAs regulating prostate cancer. MedComm-Oncol. 2:e612023.
View Article : Google Scholar
|
|
79
|
Ellis L, Lehet K, Ramakrishnan S, Adelaiye
R, Miles KM, Wang D, Liu S, Atadja P, Carducci MA and Pili R:
Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor
and hypoxia signaling associated with alterations in microRNA
expression. PLoS One. 6:e271782011. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Park H, Williams K, Trikalinos NA, Larson
S, Tan B, Waqar S, Suresh R, Morgensztern D, Van Tine BA, Govindan
R, et al: A phase I trial of temsirolimus and erlotinib in patients
with refractory solid tumors. Cancer Chemother Pharmacol.
87:337–347. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Bendell JC, Kurkjian C, Infante JR, Bauer
TM, Burris HA III, Greco FA, Shih KC, Thompson DS, Lane CM, Finney
LH and Jones SF: A phase 1 study of the sachet formulation of the
oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in
patients with advanced solid tumors. Invest New Drugs. 33:463–471.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Li S, Sheng J, Liu Z, Fan Y, Zhang C, Lv
T, Hu S, Jin J, Yu W and Song Y: Potent antitumour of the mTORC1/2
dual inhibitor AZD2014 in docetaxel-sensitive and
docetaxel-resistant castration-resistant prostate cancer cells. J
Cell Mol Med. 25:2436–2449. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Jin Y, Qu S, Tesikova M, Wang L, Kristian
A, Mælandsmo GM, Kong H, Zhang T, Jerónimo C, Teixeira MR, et al:
Molecular circuit involving KLK4 integrates androgen and mTOR
signaling in prostate cancer. Proc Natl Acad Sci USA.
110:E2572–E2581. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Pan HY and Valapala M: Regulation of
autophagy by the glycogen synthase Kinase-3 (GSK-3) signaling
pathway. Int J Mol Sci. 23:17092022. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Sun Y, Li Z and Song K: AR-mTOR-SRF axis
regulates HMMR expression in human prostate cancer cells. Biomol
Ther. 29:667–677. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Valenti MT, Mottes M, Dalle Carbonare L
and Feron O: Editorial: Bone metastases. Front Oncol.
11:7415152021. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Tanaka K, Babic I, Nathanson D, Akhavan D,
Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, et al: Oncogenic
EGFR signaling activates an mTORC2-NF-κB pathway that promotes
chemotherapy resistance. Cancer Discov. 1:524–538. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Wang Q, Tang Y, Yu H, Yin Q, Li M, Shi L,
Zhang W, Li D and Li L: CCL18 from tumor-cells promotes epithelial
ovarian cancer metastasis via mTOR signaling pathway. Mol Carcinog.
55:1688–1699. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Wei XX, Hsieh AC, Kim W, Friedlander T,
Lin AM, Louttit M and Ryan CJ: A phase I study of abiraterone
acetate combined with BEZ235, a dual PI3K/mTOR inhibitor, in
metastatic castration resistant prostate cancer. Oncologist.
22:503–e43. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Raynard C, Ma X, Huna A, Tessier N,
Massemin A, Zhu K, Flaman JM, Moulin F, Goehrig D, Medard JJ, et
al: NF-κB-dependent secretome of senescent cells can trigger
neuroendocrine transdifferentiation of breast cancer cells. Aging
Cell. 21:e136322022. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Li N, Liu Q, Han Y, Pei S, Cheng B, Xu J,
Miao X, Pan Q, Wang H, Guo J, et al: ARID1A loss induces
polymorphonuclear myeloid-derived suppressor cell chemotaxis and
promotes prostate cancer progression. Nat Commun. 13:72812022.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Dushyanthen S, Cossigny DAF and Quan GMY:
The osteoblastic and osteoclastic interactions in spinal metastases
secondary to prostate cancer. Cancer Growth Metastasis. 6:61–80.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Chen Q, Du X, Hu S and Huang Q:
NF-κB-related metabolic gene signature predicts the prognosis and
immunotherapy response in gastric cancer. Biomed Res Int.
2022:50925052022.PubMed/NCBI
|
|
94
|
Dewdney B, Jenkins MR, Best SA, Freytag S,
Prasad K, Holst J, Endersby R and Johns TG: From signalling
pathways to targeted therapies: Unravelling glioblastoma's secrets
and harnessing two decades of progress. Signal Transduct Target
Ther. 8:4002023. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Ayala G, Yan J, Li R, Ding Y, Thompson TC,
Mims MP, Hayes TG, MacDonnell V, Lynch RG, Frolov A, et al:
Bortezomib-mediated inhibition of steroid receptor coactivator-3
degradation leads to activated Akt. Clin Cancer Res. 14:7511–7518.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Nunes JJ, Pandey SK, Yadav A, Goel S and
Ateeq B: Targeting NF-kappa B signaling by artesunate restores
sensitivity of castrate-resistant prostate cancer cells to
antiandrogens. Neoplasia. 19:333–345. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Chen H, Pang B, Zhou C, Han M, Gong J, Li
Y and Jiang J: Prostate cancer-derived small extracellular vesicle
proteins: The hope in diagnosis, prognosis, and therapeutics. J
Nanobiotechnology. 21:4802023. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Rickard BP, Overchuk M, Chappell VA, Kemal
Ruhi M, Sinawang PD, Nguyen Hoang TT, Akin D, Demirci U, Franco W,
Fenton SE, et al: Methods to evaluate changes in mitochondrial
structure and function in cancer. Cancers (Basel). 15:25642023.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Gong L, Chen B, Zhang J, Sun Y, Yuan J,
Niu X, Hu G, Chen Y, Xie Z, Deng Z, et al: Human ESC-sEVs alleviate
age-related bone loss by rejuvenating senescent bone marrow-derived
mesenchymal stem cells. J Extracell Vesicles. 9:18009712020.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Martinez-Vidal L, Murdica V, Venegoni C,
Pederzoli F, Bandini M, Necchi A, Salonia A and Alfano M: Causal
contributors to tissue stiffness and clinical relevance in urology.
Commun Biol. 4:10112021. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Ma Q, Liang M, Wu Y, Dou C, Xu J, Dong S
and Luo F: Small extracellular vesicles deliver osteolytic
effectors and mediate cancer-induced osteolysis in bone metastatic
niche. J Extracell Vesicles. 10:e120682021. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Mongelli A, Atlante S, Barbi V, Bachetti
T, Martelli F, Farsetti A and Gaetano C: Treating senescence like
cancer: Novel perspectives in senotherapy of chronic diseases. Int
J Mol Sci. 21:79842020. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Gazzillo A, Volponi C, Soldani C, Polidoro
MA, Franceschini B, Lleo A, Bonavita E and Donadon M: Cellular
senescence in liver cancer: How dying cells become ‘Zombie’
enemies. Biomedicines. 12:262023. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Du D, Tang X, Li Y, Gao Y, Chen R, Chen Q,
Wen J, Wu T, Zhang Y, Lu H, et al: Senotherapy protects against
Cisplatin-induced ovarian injury by removing senescent cells and
alleviating DNA damage. Oxid Med Cell Longev. 2022:91446442022.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Gasek NS, Kuchel GA, Kirkland JL and Xu M:
Strategies for targeting senescent cells in human disease. Nat
Aging. 1:870–879. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Liu Y, Zhang Q, Ni W, Ji G and Xu H: A
strategy for the treatment of gastrointestinal cancer: Targeting
tumor senescent cells. Front Mol Biosci. 10:11398402023. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Ramírez R, Ceprian N, Figuer A, Valera G,
Bodega G, Alique M and Carracedo J: Endothelial senescence and the
chronic vascular diseases: Challenges and therapeutic opportunities
in atherosclerosis. J Pers Med. 12:2152022. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Fedorov VD, Themeli M and Sadelain M:
PD-1- and CTLA-4-based inhibitory chimeric antigen receptors
(iCARs) divert off-target immunotherapy responses. Sci Transl Med.
5:215ra1722013. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Arai S, Varkaris A, Nouri M, Chen S, Xie L
and Balk SP: MARCH5 mediates NOXA-dependent MCL1 degradation driven
by kinase inhibitors and integrated stress response activation.
eLife. 9:e549542020. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Arai S, Jonas O, Whitman MA, Corey E, Balk
SP and Chen S: Tyrosine kinase inhibitors increase MCL1 degradation
and in combination with BCLXL/BCL2 inhibitors drive prostate cancer
apoptosis. Clin Cancer Res. 24:5458–5470. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Ferraldeschi R, Welti J, Powers MV, Yuan
W, Smyth T, Seed G, Riisnaes R, Hedayat S, Wang H, Crespo M, et al:
Second-generation HSP90 inhibitor Onalespib blocks mRNA splicing of
androgen receptor variant 7 in prostate cancer cells. Cancer Res.
76:2731–2742. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Slovin S, Hussain S, Saad F, Garcia J,
Picus J, Ferraldeschi R, Crespo M, Flohr P, Riisnaes R, Lin C, et
al: Pharmacodynamic and clinical results from a phase I/II study of
the HSP90 Inhibitor Onalespib in combination with abiraterone
acetate in prostate cancer. Clin Cancer Res. 25:4624–4633. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Lu X, Yang F, Chen D, Zhao Q, Chen D, Ping
H and Xing N: Quercetin reverses docetaxel resistance in prostate
cancer via androgen receptor and PI3K/Akt signaling pathways. Int J
Biol Sci. 16:1121–1134. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Ward AB, Mir H, Kapur N, Gales DN,
Carriere PP and Singh S: Quercetin inhibits prostate cancer by
attenuating cell survival and inhibiting anti-apoptotic pathways.
World J Surg Oncol. 16:1082018. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Pratheeshkumar P, Budhraja A, Son YO, Wang
X, Zhang Z, Ding S, Wang L, Hitron A, Lee JC, Xu M, et al:
Quercetin inhibits angiogenesis mediated human prostate tumor
growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling
pathways. PLoS One. 7:e475162012. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Zhang DF, Yang ZC, Chen JQ, Jin XX, Qiu
YD, Chen XJ, Shi HY, Liu ZG, Wang MS, Liang G and Zheng XH:
Piperlongumine inhibits migration and proliferation of
castration-resistant prostate cancer cells via triggering
persistent DNA damage. BMC Complement Med Ther. 21:1952021.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Makhov P, Golovine K, Teper E, Kutikov A,
Mehrazin R, Corcoran A, Tulin A, Uzzo RG and Kolenko VM:
Piperlongumine promotes autophagy via inhibition of Akt/mTOR
signalling and mediates cancer cell death. Br J Cancer.
110:899–907. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Golovine KV, Makhov PB, Teper E, Kutikov
A, Canter D, Uzzo RG and Kolenko VM: Piperlongumine induces rapid
depletion of the androgen receptor in human prostate cancer cells.
Prostate. 73:23–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Liu G, Jin Z and Lu X: Differential
targeting of Gr-MDSCs, T cells and prostate cancer cells by
dactolisib and dasatinib. Int J Mol Sci. 21:23372020. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Araujo JC, Poblenz A, Corn P, Parikh NU,
Starbuck MW, Thompson JT, Lee F, Logothetis CJ and Darnay BG:
Dasatinib inhibits both osteoclast activation and prostate cancer
PC-3-cell-induced osteoclast formation. Cancer Biol Ther.
8:2153–2159. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Cuyàs E, Verdura S, Llorach-Pares L,
Fernández-Arroyo S, Luciano-Mateo F, Cabré N, Stursa J, Werner L,
Martin-Castillo B, Viollet B, et al: Metformin directly targets the
H3K27me3 demethylase KDM6A/UTX. Aging Cell. 17:e127722018.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Hua Y, Zheng Y, Yao Y, Jia R, Ge S and
Zhuang A: Metformin and cancer hallmarks: Shedding new lights on
therapeutic repurposing. J Transl Med. 21:4032023. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Wang ZS, Huang HR, Zhang LY, Kim S, He Y,
Li DL, Farischon C, Zhang K, Zheng X, Du ZY and Goodin S:
Mechanistic study of inhibitory effects of metformin and
atorvastatin in combination on prostate cancer cells in vitro and
in vivo. Biol Pharm Bull. 40:1247–1254. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Wang J, Lu Y, Wang J, Koch AE, Zhang J and
Taichman RS: Retraction: CXCR6 Induces prostate cancer progression
by the AKT/mammalian target of rapamycin signaling pathway. Cancer
Res. 82:3406. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Zhang J, Wu D, He Y, Li L, Liu S, Lu J,
Gui H, Wang Y, Tao Y, Wang H, et al: Rapamycin inhibits AR
signaling pathway in prostate cancer by interacting with the FK1
domain of FKBP51. Biochem Biophys Rep. 23:1007782020.PubMed/NCBI
|
|
126
|
Shorning BY, Dass MS, Smalley MJ and
Pearson HB: The PI3K-AKT-mTOR pathway and prostate cancer: At the
crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci.
21:45072020. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Lo U, Chen Y, Cen J, Deng S, Luo J, Zhau
H, Ho L, Lai CH, Mu P, Chung LWK and Hsieh JT: The driver role of
JAK-STAT signalling in cancer stemness capabilities leading to new
therapeutic strategies for therapy- and castration-resistant
prostate cancer. Clin Transl Med. 12:e9782022. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Sheth S, Jajoo S, Kaur T, Mukherjea D,
Sheehan K, Rybak LP and Ramkumar V: Resveratrol reduces prostate
cancer growth and metastasis by inhibiting the Akt/MicroRNA-21
pathway. PLoS One. 7:e516552012. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Fenner A: Prostate cancer: Resveratrol
inhibits the AR. Nat Rev Urol. 14:642. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Hickson LJ, Langhi Prata LGP, Bobart SA,
Evans TK, Giorgadze N, Hashmi SK, Herrmann SM, Jensen MD, Jia Q,
Jordan KL, et al: Senolytics decrease senescent cells in humans:
Preliminary report from a clinical trial of Dasatinib plus
Quercetin in individuals with diabetic kidney disease.
EBioMedicine. 47:446–456. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Di Micco R, Krizhanovsky V, Baker D and
d'Adda di Fagagna F: Cellular senescence in ageing: From mechanisms
to therapeutic opportunities. Nat Rev Mol Cell Biol. 22:75–95.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Kaur G, Sundar IK and Rahman I: p16-3MR: A
novel model to study cellular senescence in cigarette smoke-induced
lung injuries. Int J Mol Sci. 22:48342021. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Baker DJ, Wijshake T, Tchkonia T,
LeBrasseur NK, Childs BG, van de Sluis B, Kirkland JL and van
Deursen JM: Clearance of p16Ink4a-positive senescent cells delays
ageing-associated disorders. Nature. 479:232–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Song P, Duan JL, Ding J, Liu JJ, Fang ZQ,
Xu H, Li ZW, Du W, Xu M, Ling YW, et al: Cellular senescence primes
liver fibrosis regression through Notch-EZH2. MedComm (2020).
4:e3462023.PubMed/NCBI
|
|
135
|
Chen M, Wu G, Lu Y, Sun S, Yu Z, Pan X,
Chen W, Xu H, Qiu H, He W, et al: A p21-ATD mouse model for
monitoring and eliminating senescent cells and its application in
liver regeneration post injury. Mol Ther. Apr 6–2024.(Epub ahead of
print). View Article : Google Scholar
|
|
136
|
Zhan D, Ma D, Wei S, Lal B, Fu Y, Eberhart
C, Laterra J, Ying M, Li Y, Meeker A, et al: Monoallelic IDH1 R132H
mutation mediates glioma cell response to anticancer therapies via
induction of senescence. Mol Cancer Res. 19:1878–1888. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Chen WC, Chang TC, Chou HH, Cheng MH, Hong
JJ, Hsieh YS and Cheng CM: Peritoneal fluid analysis of advanced
ovarian cancers after hyperthermic intraperitoneal chemotherapy.
Int J Mol Sci. 24:97482023. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
D'Aguanno S and Del Bufalo D: Inhibition
of Anti-apoptotic Bcl-2 proteins in preclinical and clinical
studies: Current overview in cancer. Cells. 9:12872020. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Harrison CN, Garcia JS, Somervaille TCP,
Foran JM, Verstovsek S, Jamieson C, Mesa R, Ritchie EK, Tantravahi
SK, Vachhani P, et al: Addition of Navitoclax to ongoing
Ruxolitinib therapy for patients with myelofibrosis with
progression or suboptimal response: Phase II safety and efficacy. J
Clin Oncol. 40:1671–1680. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
He Y, Zhang X, Chang J, Kim HN, Zhang P,
Wang Y, Khan S, Liu X, Zhang X, Lv D, et al: Using
proteolysis-targeting chimera technology to reduce navitoclax
platelet toxicity and improve its senolytic activity. Nat Commun.
11:19962020. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Ferraldeschi R, Welti J, Powers MV, Yuan
W, Smyth T, Seed G, Riisnaes R, Hedayat S, Wang H, Crespo M, et al:
Second-generation HSP90 inhibitor Onalespib blocks mRNA splicing of
androgen receptor variant 7 in prostate cancer cells. Cancer Res.
76:2731–2742. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Colucci M, Zumerle S, Bressan S, Gianfanti
F, Troiani M, Valdata A, D'Ambrosio M, Pasquini E, Varesi A, Cogo
F, et al: Retinoic acid receptor activation reprograms senescence
response and enhances anti-tumor activity of natural killer cells.
Cancer Cell. 42:646–661.e9. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Chi KN, Gleave ME, Klasa R, Murray N,
Bryce C, Lopes de Menezes DE, D'Aloisio S and Tolcher AW: A phase I
dose-finding study of combined treatment with an antisense Bcl-2
oligonucleotide (Genasense) and mitoxantrone in patients with
metastatic hormone-refractory prostate cancer. Clin Cancer Res.
7:3920–3927. 2001.PubMed/NCBI
|
|
144
|
Tolcher AW, Kuhn J, Schwartz G, Patnaik A,
Hammond LA, Thompson I, Fingert H, Bushnell D, Malik S, Kreisberg
J, et al: A Phase I pharmacokinetic and biological correlative
study of oblimersen sodium (genasense, g3139), an antisense
oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients
with hormone-refractory prostate cancer. Clin Cancer Res.
10:5048–5057. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Stein MN, Goodin S, Gounder M, Gibbon D,
Moss R, Portal D, Lindquist D, Zhao Y, Takebe N, Tan A, et al: A
phase I study of AT-101, a BH3 mimetic, in combination with
paclitaxel and carboplatin in solid tumors. Invest New Drugs.
38:855–865. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Osada T, Crosby EJ, Kaneko K, Snyder JC,
Ginzel JD, Acharya CR, Yang XY, Polascik TJ, Spasojevic I, Nelson
RC, et al: HSP90-specific nIR Probe identifies aggressive prostate
cancers: Translation from preclinical models to a human phase I
study. Mol Cancer Ther. 21:217–226. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Suh GA, Lodise TP, Tamma PD, Knisely JM,
Alexander J, Aslam S, Barton KD, Bizzell E, Totten KMC, Campbell
JL, et al: Considerations for the use of phage therapy in clinical
practice. Antimicrob Agents Chemother. 66:e02071212022. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Kolodkin-Gal D, Roitman L, Ovadya Y,
Azazmeh N, Assouline B, Schlesinger Y, Kalifa R, Horwitz S,
Khalatnik Y, Hochner-Ger A, et al: Senolytic elimination of
Cox2-expressing senescent cells inhibits the growth of premalignant
pancreatic lesions. Gut. 71:345–355. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Spetsieris N, Boukovala M, Weldon JA,
Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn
PG, et al: A Phase 2 trial of abiraterone followed by randomization
to addition of dasatinib or sunitinib in men with metastatic
castration-resistant prostate cancer. Clin Genitourin Cancer.
19:22–31.e5. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Rossi M, Anerillas C, Idda ML, Munk R,
Shin CH, Donega S, Tsitsipatis D, Herman AB, Martindale JL, Yang X,
et al: Pleiotropic effects of BAFF on the senescence-associated
secretome and growth arrest. Elife. 12:e842382023. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Chaib S, Tchkonia T and Kirkland JL:
Cellular senescence and senolytics: The path to the clinic. Nat
Med. 28:1556–1568. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Kirkland JL, Tchkonia T, Zhu Y,
Niedernhofer LJ and Robbins PD: The clinical potential of senolytic
drugs. J Am Geriatr Soc. 65:2297–2301. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Ji S, Xiong M, Chen H, Liu Y, Zhou L, Hong
Y, Wang M, Wang C, Fu X and Sun X: Cellular rejuvenation: Molecular
mechanisms and potential therapeutic interventions for diseases.
Signal Transduct Target Ther. 8:1162023. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Kreienkamp R, Graziano S, Coll-Bonfill N,
Bedia-Diaz G, Cybulla E, Vindigni A, Dorsett D, Kubben N, Batista
LFZ and Gonzalo S: A cell-intrinsic interferon-like response links
replication stress to cellular aging caused by progerin. Cell Rep.
22:2006–2015. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Krtolica A, Parrinello S, Lockett S,
Desprez PY and Campisi J: Senescent fibroblasts promote epithelial
cell growth and tumorigenesis: A link between cancer and aging.
Proc Natl Acad Sci USA. 98:12072–12077. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Wang L, Jin H, Jochems F, Wang S, Lieftink
C, Martinez IM, De Conti G, Edwards F, de Oliveira RL, Schepers A,
et al: cFLIP suppression and DR5 activation sensitize senescent
cancer cells to senolysis. Nat Cancer. 3:1284–1299. 2022.
View Article : Google Scholar : PubMed/NCBI
|
